Menopause changes the body’s metabolic instructions. The timing of a response may matter.

Menopause’s effects on heart health go beyond the loss of estrogen’s protective influence. A review in Cells describes changes in gene regulation that can reshape how the body handles fats and sugar, and how blood vessels work. That’s a more consequential shift than a simple change in hormone levels, though the research doesn’t explain every step or show that any one intervention can reverse it.

How estrogen loss changes gene activity

Epigenetics helps determine which genes cells use. Two mechanisms are central: DNA methylation, in which chemical tags can silence genes, and histone modifications, which change how tightly DNA is wrapped around proteins and therefore how accessible genes are.

According to the review, estrogen helps keep certain protective genes active. Those genes help clear LDL cholesterol, maintain insulin sensitivity, and keep blood vessels flexible. As estrogen levels fall, some of those signals weaken. The resulting metabolic changes can favor fat storage, inflammation, and cardiovascular strain.

The effects show up in several ways:

• Fat processing shifts. Estrogen affects how the liver handles fat. Weaker estrogen signaling can allow triglycerides to build up in liver cells and make it harder to clear LDL cholesterol from the blood.
• Fat distribution changes. Total body fat may stay the same while more visceral fat gathers around the organs. This active fat is associated with higher disease risk.
• Insulin sensitivity can fall. Estrogen supports glucose uptake through GLUT4, a transporter that moves glucose into muscle and fat cells. With less estrogen signaling, that process can become less efficient.
• Blood vessels may stiffen. Increased DNA methylation can silence estrogen receptors in vessel walls, potentially reducing nitric oxide production and contributing to arterial stiffness and cardiovascular risk.

These shifts develop over the menopausal transition rather than appearing all at once. That gradual course makes early attention sensible, though the review doesn’t establish exactly when intervention works best for every person.

Why hormone therapy timing matters

Here’s the apparent contradiction: if estrogen supports cardiovascular health, why have early trials of hormone replacement therapy (HRT) produced mixed results?

The review points to the timing of treatment. Large studies including the Women’s Health Initiative and the Heart and Estrogen/progestin Replacement Study enrolled women who were, on average, more than a decade past menopause. By then, vascular aging and plaque buildup may already have advanced beyond what HRT could reverse.

That’s the basis of the “timing hypothesis”: starting HRT within 10 years of menopause, or before age 60, may preserve cardiovascular benefits, while starting later may not. The type of treatment may matter, too. The review says transdermal estradiol with micronized progesterone appears to have a more favorable safety profile than oral preparations, including lower blood clot risk and fewer adverse cardiovascular effects.

Steps that may support metabolic health

The review describes several approaches that may help counter these changes. None should be read as a guarantee, and decisions about medication belong in a conversation with a healthcare provider.

• Eat a Mediterranean or DASH-style diet. These patterns supply polyphenols, omega-3 fatty acids, and fiber, which can affect DNA methylation and histone modification. One trial found that a Mediterranean diet reduced major cardiovascular events by 30% among high-risk participants.
• Combine aerobic and strength exercise. Aim for at least 150 minutes of moderate aerobic activity each week and resistance training on two or more days. Strength training helps preserve muscle, which supports insulin sensitivity and metabolic flexibility.
• Discuss HRT early if it may be appropriate. Timing, delivery method, and formulation all deserve discussion with a clinician.
• Ask about targeted medicines when relevant. GLP-1 receptor agonists and SGLT2 inhibitors have shown cardiovascular benefits in postmenopausal women with diabetes. They may also affect epigenetic pathways, but that possibility needs more research.

Menopause changes more than hormone levels; it can alter how genes are expressed. The practical point is that metabolic and vascular changes unfold over time, leaving room to discuss diet, activity, and treatment options before problems become more pronounced.